India Ratings and Research (Ind-Ra) anticipates minimal credit profile impact on Indian pharma companies from potential US tariffs on pharmaceutical imports. While the US accounts for a significant portion of revenue for these companies, its contribution has been declining. Post navigation Donald Trump vs Fed governor: US President’s attempts to fire Lisa Cook might land in legal battle; Biden appointee vows not to resign Gold rate today: Gold prices rise over Rs 600 to Rs 1,00,170; why investors are flocking to the safe haven asset
